Table 4. Comparison of demographic data, disease duration, disease activity, dryness severity, pain, emotional state, insomnia level, and frequency of FMS, antibodies, and currently used drugs in PSS patient subgroups with FS scores ≥30.5 and <30.5.
| FS score >30.5 (n=23) | FS score <30.5 (n=27) | ||||||
| n | % | Mean±SD | n | % | Mean±SD | p | |
| Age (year) | 49.7±11.6 | 48.1±10.2 | 0.793 | ||||
| Disease duration (year) | 3.4±1.2 | 3.6±1.6 | 0.490 | ||||
| Disease activity | |||||||
| ESSDAI | 3.3±1.6 | 4.4±1.9 | 0.016 | ||||
| Dryness severity | |||||||
| Schirmer (mean) | 8.9±7.5 | 10.1±7.4 | 0.453 | ||||
| WUSFR | 1.0±1.3 | 0.8±0.6 | 0.777 | ||||
| Pain | |||||||
| pain thresholds (mean) | 9.8±3.5 | 8.8±3.3 | 0.242 | ||||
| PDQ | 4.7±5.2 | 11.1±6.9 | 0.001 | ||||
| NPBS | 3.1±2.3 | 5.0±2.6 | 0.010 | ||||
| Emotional state | |||||||
| BDI | 5.5±5.8 | 14.2±7.6 | <0.001 | ||||
| BAI | 7.3±5.9 | 15.1±8.5 | <0.001 | ||||
| Insomnia | |||||||
| ISI | 6.3±4.1 | 12.3±6.0 | <0.001 | ||||
| Frequency | |||||||
| Female | 21 | 91.3 | 27 | 100.0 | 0.207 | ||
| FMS1 | 1 | 4.3 | 14 | 51.9 | <0.001 | ||
| NP (PDQ >18)† | 0 | 0 | 5 | 18.5 | 0.030 | ||
| MD (BDI >11) § | 3 | 13.1 | 19 | 70.4 | <0.001 | ||
| Anxiety (BAI >22)◊ | 1 | 4.3 | 6 | 22.2 | 0.069 | ||
| Insomnia (ISI >14)° | 1 | 4.3 | 11 | 40.7 | 0.003 | ||
| ANA | 20 | 87.0 | 24 | 88.9 | 0.834 | ||
| SSA | 17 | 73.9 | 21 | 77.8 | 0.750 | ||
| SSB | 8 | 34.8 | 10 | 37.0 | 0.869 | ||
| Hydroxychloroquine | 22 | 95.7 | 23 | 85.0 | 0.219 | ||
| Corticosteroid | 8 | 34.8 | 10 | 37.0 | 0.869 | ||
| Duloxetine | 7 | 30.4 | 12 | 44.4 | 0.309 | ||
| Pregabalin | 2 | 8.7 | 3 | 11.1 | 0.777 | ||
| FMS: Fibromyalgia syndrome; PSS: Primary Sjögren’s syndrome; FS: Fatigue subscale; SD: Standard deviation; ESSDAI: EULAR Sjögren’s syndrome disease activity index; ESSPRI: EULAR Sjögren’s Syndrome Patient Reported Index; WUSFR: Whole unstimulated salivary flow rate; PDQ: Pain DETECT questionnaire; NPBS: Number of painful body sites; BDI: Beck Depression Inventory; BAI: Beck Anxiety Inventory; ISI: Insomnia Severity Index; 1 The Analgesic; Anesthetic, and Addiction Clinical Trial Translations Innovations Opportunities and Networks-American Pain Society Pain Taxonomy criteria; NP: Neuropathic pain; † Neuropathic pain component is likely (>90%); MD: Mood disturbance; § From mild mood disturbance to extreme depression; ◊ Moderate to severe anxiety; ° Moderate and severe insomnia, indicating clinically significant insomnia. | |||||||